Letters sent to healthcare professionals in April 2016

In April 2016, letters were sent regarding canagliflozin (Invokana鈻�, Vokanamet鈻�), BCR-ABL tyrosine kinase inhibitors, pomalidomide (滨尘苍辞惫颈诲鈻�), and retigabine (Trobalt)

From:
Medicines and Healthcare products Regulatory Agency
Published
10 May 2016
Therapeutic area:
Cancer, Endocrinology, diabetology and metabolism, Infectious disease, Neurology and Ophthalmology

In April 2016, letters were sent to healthcare professionals regarding:

  • canagliflozin-containing medicines (): risk of lower limb amputation (primarily of the toe)
  • BCR-ABL tyrosine kinase inhibitors () and risk of hepatitis B reactivation: screen patients for hepatitis B virus before treatment - see also
  • pomalidomide (): hepatitis B virus status to be established before initiating treatment - see also
  • retigabine (): risk acquired vitelliform maculopathy

Article citation: Drug Safety Update Vol 9 issue 10 May 2016 4.

Updates to this page

Published 10 May 2016